Conflicts of interest J.-P.O. has received reimbursements from Wyeth for symposia, speaking and consulting. A.T. has received reimbursement from Wyeth for organizing education and for research-related staffing. A.D.O. has received fees from Wyeth for speaking and research. D.R., J.F., R.P., C.M. and B.F. are employees of Wyeth and hold stock in Wyeth.
Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept
Version of Record online: 21 MAY 2009
© 2009 Wyeth Research. Journal Compilation © 2009 British Association of Dermatologists
British Journal of Dermatology
Volume 161, Issue 5, pages 1190–1195, November 2009
How to Cite
Ortonne, J.-P., Taïeb, A., Ormerod, A.D., Robertson, D., Foehl, J., Pedersen, R., Molta, C. and Freundlich, B. (2009), Patients with moderate-to-severe psoriasis recapture clinical response during re-treatment with etanercept. British Journal of Dermatology, 161: 1190–1195. doi: 10.1111/j.1365-2133.2009.09238.x
- Issue online: 20 OCT 2009
- Version of Record online: 21 MAY 2009
- Accepted for publication 3 April 2009
Background Patients with psoriasis experience remission and gradual reappearance of erythematous and scaly plaques and require individualized treatment over time. A goal of psoriasis treatment is to provide optimal efficacy with a flexible therapeutic regimen that may include treatment pauses.
Objectives To determine whether patients receiving initial treatment with etanercept who then pause therapy would subsequently recapture response during re-treatment.
Patients and methods A post-hoc analysis of 226 patients with moderate-to-severe psoriasis from a large multicentre trial was performed. Patients had received etanercept 50 mg twice weekly subcutaneously until a target clinical response had been achieved, then had paused treatment and eventually relapsed. They were then re-treated with etanercept 25 mg twice weekly. The number of patients recapturing a Physician Global Assessment (PGA) of psoriasis rating of ≤ 2 (clear, almost clear or mild) on first re-treatment was assessed. Patient satisfaction during the initial treatment and first re-treatment period was also determined.
Results A total of 187 (83%) patients recaptured the target clinical response of a PGA of ≤ 2 after re-treatment. The majority of patients [219 of 226 (97%)] reported satisfaction with etanercept re-treatment. No new safety concerns emerged during re-treatment.
Conclusions In this post-hoc analysis, patients with psoriasis who were re-treated with etanercept 25 mg twice weekly effectively recaptured clinical responses that patients found satisfactory. A flexible treatment option is available to dermatologists and patients for individualized care.